You are here


CVC, Temasek 'exploring options' for Alvogen

Hong Kong

ALVOGEN'S owners - including CVC Capital Partners and Temasek Holdings - are said to be exploring options for the generic pharmaceutical company, which could be valued at about US$4 billion, according to people familiar with the matter.


BT is now on Telegram!

For daily updates on weekdays and specially selected content for the weekend. Subscribe to